Seaweed Sugar Compound Fights Brain Aging Through the Gut Microbiome

Age-related neuroinflammation is a key driver of cognitive decline, and the gut-brain axis has emerged as a critical, modifiable pathway in this process. Finding dietary compounds that can favorably reshape gut microbiota and thereby protect the aging brain represents a major opportunity in longevity medicine.

This study investigated sulfated fucooligosaccharides (FOS), oligosaccharide compounds derived from marine algae, in a well-established d-galactose-induced mouse model of aging. Mice received FOS supplementation, and researchers assessed behavioral outcomes, neuroinflammatory markers, gut barrier integrity, and microbiome composition.

FOS treatment produced significant improvements across multiple domains. In the brain, FOS reduced microglial activation and suppressed key inflammatory mediators including P38 MAPK, CREB, COX-2, and PGE2. Simultaneously, FOS lowered NF-κB and TLR4 signaling — pathways triggered when gut-derived lipopolysaccharide leaks into circulation. In the gut, FOS repaired the intestinal mucosal barrier, reduced lipopolysaccharide release, increased microbial diversity, and strongly promoted growth of Akkermansia, a genus associated with improved metabolic and inflammatory health. FOS also elevated butyric acid levels and reduced HDAC3 expression, suggesting an epigenetic component to its anti-inflammatory action.

Critically, fecal microbiota transplantation from FOS-treated mice into untreated aging mice reproduced the neuroprotective and cognitive benefits, providing strong mechanistic evidence that the gut microbiome mediates FOS's brain effects rather than direct action.

These findings are meaningful for longevity research, highlighting seaweed-derived oligosaccharides as accessible, food-based compounds capable of modulating the gut-brain axis. However, results are from a mouse model only, and translation to human aging physiology requires clinical validation.